Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic.
Identifieur interne : 000176 ( PubMed/Checkpoint ); précédent : 000175; suivant : 000177Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic.
Auteurs : Eakachai Prompetchara [Thaïlande] ; Chutitorn Ketloy [Thaïlande] ; Tanapat Palaga [Thaïlande]Source :
- Asian Pacific journal of allergy and immunology [ 0125-877X ] ; 2020.
Descripteurs français
- KwdFr :
- Coronavirus du syndrome respiratoire du Moyen-Orient, Humains, Immunité acquise, Immunité innée, Infections à coronavirus (), Infections à coronavirus (immunologie), Interactions hôte-pathogène, Pneumopathie virale (immunologie), Syndrome respiratoire aigu sévère, Vaccins antiviraux (immunologie), Virus du SRAS, Échappement immunitaire, Épidémies.
- MESH :
- immunologie : Infections à coronavirus, Pneumopathie virale, Vaccins antiviraux.
- Coronavirus du syndrome respiratoire du Moyen-Orient, Humains, Immunité acquise, Immunité innée, Infections à coronavirus, Interactions hôte-pathogène, Syndrome respiratoire aigu sévère, Virus du SRAS, Échappement immunitaire, Épidémies.
English descriptors
- KwdEn :
- Adaptive Immunity, Betacoronavirus (immunology), Coronavirus Infections (immunology), Coronavirus Infections (prevention & control), Epidemics, Host-Pathogen Interactions, Humans, Immune Evasion, Immunity, Innate, Middle East Respiratory Syndrome Coronavirus, Pneumonia, Viral (immunology), SARS Virus, Severe Acute Respiratory Syndrome, Viral Vaccines (immunology).
- MESH :
- chemical , immunology : Viral Vaccines.
- immunology : Betacoronavirus, Coronavirus Infections, Pneumonia, Viral.
- prevention & control : Coronavirus Infections.
- Adaptive Immunity, Epidemics, Host-Pathogen Interactions, Humans, Immune Evasion, Immunity, Innate, Middle East Respiratory Syndrome Coronavirus, SARS Virus, Severe Acute Respiratory Syndrome.
Abstract
As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS. The rapid genomic sequencing and open access data, together with advanced vaccine technology, are expected to give us more knowledge on the pathogen itself, including the host immune response as well as the plan for therapeutic vaccines in the near future. This review aims to provide a comparative view among SARS-CoV, MERS-CoV and the newly epidemic SARS-CoV-2, in the hope to gain a better understanding of the host-pathogen interaction, host immune responses, and the pathogen immune evasion strategies. This predictive view may help in designing an immune intervention or preventive vaccine for COVID-19 in the near future.
DOI: 10.12932/AP-200220-0772
PubMed: 32105090
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:32105090Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic.</title>
<author><name sortKey="Prompetchara, Eakachai" sort="Prompetchara, Eakachai" uniqKey="Prompetchara E" first="Eakachai" last="Prompetchara">Eakachai Prompetchara</name>
<affiliation wicri:level="1"><nlm:affiliation>Center of Excellence in Vaccine Research and Development (Chula Vaccine Research Center Chula VRC), Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>Center of Excellence in Vaccine Research and Development (Chula Vaccine Research Center Chula VRC), Faculty of Medicine, Chulalongkorn University, Bangkok 10330</wicri:regionArea>
<wicri:noRegion>Bangkok 10330</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ketloy, Chutitorn" sort="Ketloy, Chutitorn" uniqKey="Ketloy C" first="Chutitorn" last="Ketloy">Chutitorn Ketloy</name>
<affiliation wicri:level="1"><nlm:affiliation>Center of Excellence in Vaccine Research and Development (Chula Vaccine Research Center Chula VRC), Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>Center of Excellence in Vaccine Research and Development (Chula Vaccine Research Center Chula VRC), Faculty of Medicine, Chulalongkorn University, Bangkok 10330</wicri:regionArea>
<wicri:noRegion>Bangkok 10330</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Palaga, Tanapat" sort="Palaga, Tanapat" uniqKey="Palaga T" first="Tanapat" last="Palaga">Tanapat Palaga</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology, Faculty of Science, Chulalongkorn University, Bangkok 10330, Thailand.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>Department of Microbiology, Faculty of Science, Chulalongkorn University, Bangkok 10330</wicri:regionArea>
<wicri:noRegion>Bangkok 10330</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32105090</idno>
<idno type="pmid">32105090</idno>
<idno type="doi">10.12932/AP-200220-0772</idno>
<idno type="wicri:Area/PubMed/Corpus">000215</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000215</idno>
<idno type="wicri:Area/PubMed/Curation">000215</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000215</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000176</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000176</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic.</title>
<author><name sortKey="Prompetchara, Eakachai" sort="Prompetchara, Eakachai" uniqKey="Prompetchara E" first="Eakachai" last="Prompetchara">Eakachai Prompetchara</name>
<affiliation wicri:level="1"><nlm:affiliation>Center of Excellence in Vaccine Research and Development (Chula Vaccine Research Center Chula VRC), Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>Center of Excellence in Vaccine Research and Development (Chula Vaccine Research Center Chula VRC), Faculty of Medicine, Chulalongkorn University, Bangkok 10330</wicri:regionArea>
<wicri:noRegion>Bangkok 10330</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ketloy, Chutitorn" sort="Ketloy, Chutitorn" uniqKey="Ketloy C" first="Chutitorn" last="Ketloy">Chutitorn Ketloy</name>
<affiliation wicri:level="1"><nlm:affiliation>Center of Excellence in Vaccine Research and Development (Chula Vaccine Research Center Chula VRC), Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>Center of Excellence in Vaccine Research and Development (Chula Vaccine Research Center Chula VRC), Faculty of Medicine, Chulalongkorn University, Bangkok 10330</wicri:regionArea>
<wicri:noRegion>Bangkok 10330</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Palaga, Tanapat" sort="Palaga, Tanapat" uniqKey="Palaga T" first="Tanapat" last="Palaga">Tanapat Palaga</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology, Faculty of Science, Chulalongkorn University, Bangkok 10330, Thailand.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>Department of Microbiology, Faculty of Science, Chulalongkorn University, Bangkok 10330</wicri:regionArea>
<wicri:noRegion>Bangkok 10330</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Asian Pacific journal of allergy and immunology</title>
<idno type="ISSN">0125-877X</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adaptive Immunity</term>
<term>Betacoronavirus (immunology)</term>
<term>Coronavirus Infections (immunology)</term>
<term>Coronavirus Infections (prevention & control)</term>
<term>Epidemics</term>
<term>Host-Pathogen Interactions</term>
<term>Humans</term>
<term>Immune Evasion</term>
<term>Immunity, Innate</term>
<term>Middle East Respiratory Syndrome Coronavirus</term>
<term>Pneumonia, Viral (immunology)</term>
<term>SARS Virus</term>
<term>Severe Acute Respiratory Syndrome</term>
<term>Viral Vaccines (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term>
<term>Humains</term>
<term>Immunité acquise</term>
<term>Immunité innée</term>
<term>Infections à coronavirus ()</term>
<term>Infections à coronavirus (immunologie)</term>
<term>Interactions hôte-pathogène</term>
<term>Pneumopathie virale (immunologie)</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Vaccins antiviraux (immunologie)</term>
<term>Virus du SRAS</term>
<term>Échappement immunitaire</term>
<term>Épidémies</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
<term>Vaccins antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Betacoronavirus</term>
<term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adaptive Immunity</term>
<term>Epidemics</term>
<term>Host-Pathogen Interactions</term>
<term>Humans</term>
<term>Immune Evasion</term>
<term>Immunity, Innate</term>
<term>Middle East Respiratory Syndrome Coronavirus</term>
<term>SARS Virus</term>
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term>
<term>Humains</term>
<term>Immunité acquise</term>
<term>Immunité innée</term>
<term>Infections à coronavirus</term>
<term>Interactions hôte-pathogène</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Virus du SRAS</term>
<term>Échappement immunitaire</term>
<term>Épidémies</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS. The rapid genomic sequencing and open access data, together with advanced vaccine technology, are expected to give us more knowledge on the pathogen itself, including the host immune response as well as the plan for therapeutic vaccines in the near future. This review aims to provide a comparative view among SARS-CoV, MERS-CoV and the newly epidemic SARS-CoV-2, in the hope to gain a better understanding of the host-pathogen interaction, host immune responses, and the pathogen immune evasion strategies. This predictive view may help in designing an immune intervention or preventive vaccine for COVID-19 in the near future.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32105090</PMID>
<DateCompleted><Year>2020</Year>
<Month>03</Month>
<Day>24</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0125-877X</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>38</Volume>
<Issue>1</Issue>
<PubDate><Year>2020</Year>
<Month>Mar</Month>
</PubDate>
</JournalIssue>
<Title>Asian Pacific journal of allergy and immunology</Title>
<ISOAbbreviation>Asian Pac. J. Allergy Immunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic.</ArticleTitle>
<Pagination><MedlinePgn>1-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.12932/AP-200220-0772</ELocationID>
<Abstract><AbstractText>As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS. The rapid genomic sequencing and open access data, together with advanced vaccine technology, are expected to give us more knowledge on the pathogen itself, including the host immune response as well as the plan for therapeutic vaccines in the near future. This review aims to provide a comparative view among SARS-CoV, MERS-CoV and the newly epidemic SARS-CoV-2, in the hope to gain a better understanding of the host-pathogen interaction, host immune responses, and the pathogen immune evasion strategies. This predictive view may help in designing an immune intervention or preventive vaccine for COVID-19 in the near future.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Prompetchara</LastName>
<ForeName>Eakachai</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Center of Excellence in Vaccine Research and Development (Chula Vaccine Research Center Chula VRC), Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Center of Excellence in Vaccine Research and Development (Chula Vaccine Research Center Chula VRC), Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Vaccines and Therapeutic Proteins Research Group, the Special Task Force for Activating Research (STAR), Chulalongkorn University, Bangkok 10330, Thailand.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ketloy</LastName>
<ForeName>Chutitorn</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Center of Excellence in Vaccine Research and Development (Chula Vaccine Research Center Chula VRC), Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Center of Excellence in Vaccine Research and Development (Chula Vaccine Research Center Chula VRC), Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Palaga</LastName>
<ForeName>Tanapat</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology, Faculty of Science, Chulalongkorn University, Bangkok 10330, Thailand.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Center of Excellence in Immunology and Immune-mediated Diseases, Chulalongkorn University, Bangkok 10330, Thailand.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>Thailand</Country>
<MedlineTA>Asian Pac J Allergy Immunol</MedlineTA>
<NlmUniqueID>8402034</NlmUniqueID>
<ISSNLinking>0125-877X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C000669933">COVID-19 vaccine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName>
<SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D056704" MajorTopicYN="Y">Adaptive Immunity</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058872" MajorTopicYN="N">Epidemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D054884" MajorTopicYN="N">Host-Pathogen Interactions</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057131" MajorTopicYN="N">Immune Evasion</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007113" MajorTopicYN="Y">Immunity, Innate</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D065207" MajorTopicYN="N">Middle East Respiratory Syndrome Coronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>2</Month>
<Day>28</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>3</Month>
<Day>25</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>2</Month>
<Day>28</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32105090</ArticleId>
<ArticleId IdType="doi">10.12932/AP-200220-0772</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Thaïlande</li>
</country>
</list>
<tree><country name="Thaïlande"><noRegion><name sortKey="Prompetchara, Eakachai" sort="Prompetchara, Eakachai" uniqKey="Prompetchara E" first="Eakachai" last="Prompetchara">Eakachai Prompetchara</name>
</noRegion>
<name sortKey="Ketloy, Chutitorn" sort="Ketloy, Chutitorn" uniqKey="Ketloy C" first="Chutitorn" last="Ketloy">Chutitorn Ketloy</name>
<name sortKey="Palaga, Tanapat" sort="Palaga, Tanapat" uniqKey="Palaga T" first="Tanapat" last="Palaga">Tanapat Palaga</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000176 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000176 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= MersV1 |flux= PubMed |étape= Checkpoint |type= RBID |clé= pubmed:32105090 |texte= Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:32105090" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a MersV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |